MedGenesis Therapeutix, a biotechnology company, has received a grant from the Deutsche Parkinson Vereinigung e.V. for the Phase II development of glial cell line derived neurotrophic factor (GDNF). MedGenesis chairman and CEO Dr. Erich ...
Tags: Advance Gdnf, MedGenesis Therapeutix, Parkinson's disease